Salute e Benessere | Diffusione Gratuita di Comunicati Stampa in inglese| Pubblica i tuoi comunicati con informazione.news

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative…

® have been delivered. PYLCLARI® (INN: Piflufolastat ( 18 F) also known as ( 18 F)-DCFPyL), is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical settings:Primary staging of patients with high-risk prostate cancer prior to initial curative therapyTo localize recurrence of prostate cancer in patients with a suspected recurrence based on...

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2024

Accumulated revenue for January – April 2024 increased by 20 % to SEK 618.2 (514.9) million. Accumulated revenue for January –April 2024increased by 20 % toSEK 618.2(514.9) million. Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West Europe :Cyprus,France,Greece,Italy,...

21st.BIO unveils a new pilot plant facility to accelerate impact of biotech…

Why do we need pilot facilities? Upscaling mistakes cost a lot of money and time Why do we need pilot facilities? Upscaling mistakes cost a lot of money and time "In this industry, upscaling mistakes cost a lot of money and time," explainsThomas Schmidt, co-founder, and CEO at 21st.BIO. "For our customers, it's all about getting the next step right. The ability to increase productivity when also moving up in scale is what distinguishes good from great." 21st.BIO offers this…

World Lupus Federation Global Survey Finds 91% of People with Lupus Report Using…

The survey results revealed that a significant percentage of respondents (75%) have been using steroids for over a year, and 27% have been using them for over a decade. Additionally, 43% of the respondents reported taking above the recommended maintenance doses (5-7.5mg) of steroids as their typical everyday dose, and 58% reported taking maximum dosages of 30 mg or higher. An overwhelming number of survey respondents (96%) reported being concerned about the long-term effects of steroid use…

Red light therapy for repairing spinal cord injury passes milestone

Their latest research, published in Bioengineering and Translational Medicine, determined an optimal 'dose' for this novel approach, and showed it can deliver therapeutic improvements including significant restoration of sensation and movement, and regeneration of damaged nerve cells. Their latest research, published in Bioengineering and Translational Medicine, determined an optimal 'dose' for this novel approach, and showed it can deliver therapeutic improvements including significant...

Calliditas announces positive topline results of Phase 2 head and neck cancer…

The treatment groups were well-balanced with no clinically relevant differences between the groups observed at baseline. Patients treated with pembrolizumab and setanaxib showed statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statistically significant improvement in overall survival (OS at 6 months 92% vs 68%; OS at 9 months 88% vs 58%; Hazard ratio=0.45) compared to patients…

Cellectis Announces Completion of the Additional Equity Investment by…

Completion of theadditional equityinvestmentof$140MbyAstraZeneca, aspreviouslyannouncedonNovember 1and 15, 2023NEW YORK, May06, 2024(GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that, following clearance from the French Ministry of Economy and satisfaction of all other closing conditions,...

Health Canada Approves Nexstim NBS 6 System for Treatment of MDD

Press release, Helsinki, 6 May 2024 at 9 AM (EEST)Health Canada Approves Nexstim NBS 6 System for Treatment of MDD Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received approval from Health Canada for the marketing and commercial distribution of its NBS 6 system for the treatment of Major Depressive Disorder (MDD).Released in the EU and the United States in 2023, the NBS 6 is a new generation Nexstim system. The NBS 6 is currently FDA-approved for the treatment of...

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

VALNEVADeclaration of shares and voting rightsApril 30, 2024__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: May 6, 2024 Number of sharescomposing the share capital of ValnevaTotal number of voting rights including suspended voting rights* Description of the change...

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to…

The three-year initiative was announced at the Novo Nordisk Foundation's Global Science Summit in Denmark, where each organization committed US$100 million, for a total of US$300 million. Initial funding will support solutions to address the health impacts of climate change; infectious disease and antimicrobial resistance (AMR); and greater understanding of the interplay between nutrition, immunity, disease, and developmental outcomes. The three-year initiative was announced at the Novo…

BioVaxys Technology Corp. Closes First Tranche of Private Placement

Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole common share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until May 3, 2026, being the date that is 24 months from the date of issue. Each Unit consists of one common share in the capital of the Company (each, a " Share ") and one whole common share purchase warrant (each, a "…

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Bagsværd, Denmark, 3 May 2024— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares...

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market…

Since receiving Fast Track Designation from the FDA in late 2022 for its leading cancer treatment, pelareorep, in the treatment of pancreatic cancer, Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has maintained strong progress. The company recently announced that it has requested a Type C meeting with the FDA to discuss an upcoming registration-enabling trial of pelareorep for treating HR+/HER2- metastatic breast cancer (mBC) patients. Since receivingFast Track Designation from theFDA...

Brains Bioceutical Announces the Addition of Industry Veteran John Boshart to…

Orion Corporation: Managers' transactions – Hilpi Rautelin

Boehringer Ingelheim shares positive results from the first study worldwide in…

Orion Corporation: Managers' transactions – Ari Lehtoranta

Orion Corporation: Managers' transactions – Karen Lykke Sørensen

Orion Corporation: Managers' transactions – Kari Jussi Aho

Orion Corporation: Managers' transactions – Veli-Matti Mattila

Orion Corporation: Managers' transactions – Eija Ronkainen

Orion Corporation: Managers' transactions – Maziar Mike Doustdar

Orion Corporation: Managers' transactions – Henrik Stenqvist

Virbac : Declaration of the number of shares and voting rights

Curium Announces First Commercial Doses in Germany of PYLCLARI® – An Innovative…

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT APRIL 2024

21st.BIO unveils a new pilot plant facility to accelerate impact of biotech…

World Lupus Federation Global Survey Finds 91% of People with Lupus Report Using…

Red light therapy for repairing spinal cord injury passes milestone

Calliditas announces positive topline results of Phase 2 head and neck cancer…

Cellectis Announces Completion of the Additional Equity Investment by…

Health Canada Approves Nexstim NBS 6 System for Treatment of MDD

Declaration of shares and voting rights April 30, 2024 - VALNEVA SE

Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to…

BioVaxys Technology Corp. Closes First Tranche of Private Placement

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market…